130 related articles for article (PubMed ID: 3437102)
1. Effect of the aldehyde dehydrogenase inhibitor, cyanamide, on the ex vivo sensitivity of murine multipotent and committed hematopoietic progenitor cells to mafosfamide (ASTA Z 7557).
Kohn FR; Landkamer GJ; Sladek NE
Immunopharmacol Immunotoxicol; 1987; 9(2-3):163-76. PubMed ID: 3437102
[TBL] [Abstract][Full Text] [Related]
2. Effect of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of human multipotent and committed hematopoietic progenitor cells and malignant blood cells to oxazaphosphorines.
Kohn FR; Landkamer GJ; Manthey CL; Ramsay NK; Sladek NE
Cancer Res; 1987 Jun; 47(12):3180-5. PubMed ID: 3034402
[TBL] [Abstract][Full Text] [Related]
3. Effects of aldehyde dehydrogenase inhibitors on the ex vivo sensitivity of murine late spleen colony-forming cells (day-12 CFU-S) and hematopoietic repopulating cells to mafosfamide (ASTA Z 7557).
Kohn FR; Sladek NE
Biochem Pharmacol; 1987 Sep; 36(17):2805-11. PubMed ID: 2820422
[TBL] [Abstract][Full Text] [Related]
4. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines.
Kohn FR; Sladek NE
Biochem Pharmacol; 1985 Oct; 34(19):3465-71. PubMed ID: 2996550
[TBL] [Abstract][Full Text] [Related]
5. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity of aldehyde dehydrogenases in murine tumor and hematopoietic progenitor cells to inhibition by chloral hydrate as determined by the ability of chloral hydrate to potentiate the cytotoxic action of mafosfamide.
Maki PA; Sladek NE
Biochem Pharmacol; 1993 Jan; 45(1):231-9. PubMed ID: 8424816
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of the cytotoxic action of mafosfamide by N-isopropyl-p-formylbenzamide, a metabolite of procarbazine.
Maki PA; Sladek NE
Cancer Res; 1991 Aug; 51(16):4170-5. PubMed ID: 1868438
[TBL] [Abstract][Full Text] [Related]
8. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
[TBL] [Abstract][Full Text] [Related]
9. Regulation of early hematopoiesis in serum-deprived cultures of mafosfamide-treated and untreated CD34-enriched bone marrow cells.
Ottmann OG; Stella CC; Eder M; Reutzel P; Ströcker S; Hoelzer D; Ganser A
Exp Hematol; 1991 Sep; 19(8):773-8. PubMed ID: 1714403
[TBL] [Abstract][Full Text] [Related]
10. In vitro purging of bone marrow with mafosfamide synergizes with in vivo chemotherapy to delay the hematological recovery in a murine model of autologous bone marrow transplantation.
Lopez M; Mary JY; Sainteny F
Exp Hematol; 1993 Feb; 21(2):311-8. PubMed ID: 8425567
[TBL] [Abstract][Full Text] [Related]
11. In vitro sensitivity of human hematopoietic progenitor cells to 4-hydroperoxycyclophosphamide.
Ratajczak MZ; Ratajczak J; Kuczynski W; Light B; Lusk EJ; Gewirtz AM
Exp Hematol; 1993 Dec; 21(13):1663-7. PubMed ID: 8243568
[TBL] [Abstract][Full Text] [Related]
12. The effect of a combined purging with mafosfamide and hyperthermia on murine haemopoietic stem cells and leukaemogenic cells.
Gidáli J; Fehér I
Bone Marrow Transplant; 1992 Dec; 10(6):479-83. PubMed ID: 1490197
[TBL] [Abstract][Full Text] [Related]
13. The opposing actions in vivo on murine myelopoiesis of purified preparations of lactoferrin and the colony stimulating factors.
Broxmeyer HE; Williams DE; Hangoc G; Cooper S; Gentile P; Shen RN; Ralph P; Gillis S; Bicknell DC
Blood Cells; 1987; 13(1-2):31-48. PubMed ID: 3499193
[TBL] [Abstract][Full Text] [Related]
14. Effects of in vivo treatment with PIXY321 (GM-CSF/IL-3 fusion protein) on proliferation kinetics of bone marrow and blood myeloid progenitor cells in patients with sarcoma.
Broxmeyer HE; Benninger L; Cooper S; Hague N; Benjamin RS; Vadhan-Raj S
Exp Hematol; 1995 Apr; 23(4):335-40. PubMed ID: 7895781
[TBL] [Abstract][Full Text] [Related]
15. The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma.
Broxmeyer HE; Williams DE; Lu L; Cooper S; Anderson SL; Beyer GS; Hoffman R; Rubin BY
J Immunol; 1986 Jun; 136(12):4487-95. PubMed ID: 3086433
[TBL] [Abstract][Full Text] [Related]
16. The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. II. The influence of lymphokines on CFU-GM colonies from human untreated, ASTA-Z or Campath-1M treated bone marrow.
Mumcuoglu M; Naparstek E; Slavin S
Bone Marrow Transplant; 1990 Mar; 5(3):153-8. PubMed ID: 2184907
[TBL] [Abstract][Full Text] [Related]
17. Thy-1 is a differentiation antigen that characterizes immature murine erythroid and myeloid hematopoietic progenitors.
Miller BA; Lipton JM; Linch DC; Burakoff SJ; Nathan DG
J Cell Physiol; 1985 Apr; 123(1):25-32. PubMed ID: 2857726
[TBL] [Abstract][Full Text] [Related]
18. Restoration of sensitivity to oxazaphosphorines by inhibitors of aldehyde dehydrogenase activity in cultured oxazaphosphorine-resistant L1210 and cross-linking agent-resistant P388 cell lines.
Sladek NE; Landkamer GJ
Cancer Res; 1985 Apr; 45(4):1549-55. PubMed ID: 3978623
[TBL] [Abstract][Full Text] [Related]
19. Characterization of late and early hematopoietic progenitor/stem cell sensitivity to mafosfamide.
Douay L; Giarratana MC; Labopin M; Bardinet D; Bouchet S; Gorin NC
Bone Marrow Transplant; 1995 May; 15(5):769-75. PubMed ID: 7670404
[TBL] [Abstract][Full Text] [Related]
20. Effects of recombinant human tumor necrosis factor on highly enriched hematopoietic progenitor cell populations from normal human bone marrow and peripheral blood and bone marrow from patients with chronic myeloid leukemia.
Wisniewski D; Strife A; Atzpodien J; Clarkson BD
Cancer Res; 1987 Sep; 47(18):4788-94. PubMed ID: 3040231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
